Navigation Links
Promising Results in Treating Facial Bruising From Injectables
Date:9/26/2007

Top physician leading clinical trials

FREEPORT, N.Y., Sept. 26 /PRNewswire/ -- Physicians nationwide report promising results in treating facial bruising from injectable cosmetic treatments by using Pinoxide(TM), an active ingredient best known for treating under-eye circles.

Pinoxide is a proprietary blend of bicyclic monoterpene dials (BMTd) created by AGI Dermatics and formulated in the company's Remergent Microcirculation Therapy product. Pinoxide has been clinically proven to speed blood flow, warm the skin, increase resistance to cold, and reduce dark under- eye symptoms. Additional research suggests Pinoxide may also contribute to promoting firmness and resiliency in the skin. Now, physicians are studying the ingredient's ability to heal bruising.

Dr. Mark G. Rubin, a board-certified dermatologist currently practicing at the Lasky Clinic in Beverly Hills, is conducting the clinical trials on Pinoxide, applying the Microcirculation Therapy formula to the injection site immediately after use of skin fillers such as collagen, Restylane and Juvederm, or Botox.

"Anatomically speaking, dark circles are like bruises - so the science behind using Pinoxide for bruising makes total sense," said Dr. Rubin. "The skin discoloration during bruising is the result of blood leaking from damaged blood vessels and surfacing to the skin. Similarly, blood vessels under the eyes can burst, leading to the appearance of unattractive dark circles."

Leading dermatologists share Dr. Rubin's opinion. Dr. Thomas Francel, a board certified plastic surgeon, has found that application of MicroCirculation Therapy on his patients reduces the appearance of skin bruising, and decreases the amount of healing time for the bruise. Dr. Francel is the Chief of Plastic Surgery at St. John's Mercy Medical Center and an Associate Professor of Surgery at St. Louis University.

Injectable cosmetic treatments are among the five top most requested aesthetic treatments nationwide last year. According to the American Society for Aesthetic Plastic Surgery, more than 5 million women had injectable cosmetic treatments last year. Bruising is a common temporary side effect.

AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  As National Nutrition Month ... the Company is helping people live healthier lives ... prescription savings programs in all 50 states including:  ... Program  and  California Prescription Assistance Program . ... Columbia University for nutritious eating habits: ...
(Date:2/23/2017)... Feb. 23, 2017  MiMedx Group, Inc. (NASDAQ: MDXG), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and Dental sectors of healthcare, today ... full year ended December 31, 2016. Full ... is a 31% increase over full year 2015 revenue ...
(Date:2/23/2017)... , Feb. 23, 2017 LG Innotek today announced that ... sterilization applications. As its sterilization performance is 1.5 times higher than ... wavelength ultraviolet rays in the range of 200 -- 280nm, allowing it ... bacteria by destroying their DNA. LG Innotek,s product emits UV in ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... Emeryville, CA (PRWEB) , ... February 24, 2017 ... ... Esparza for qualifying into the Senior International Elite division on February 12th. ... All Around divisions at the elite qualifier competition held in Las Vegas, Nevada. ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be ... 2016 National Education Policy Center Bunkum Award. We invite you to enjoy our 11th ... year’s Bunkum winner is the Center for American Progress (CAP), for its report, Lessons ...
(Date:2/23/2017)... ... ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing ... which will begin airing on February 24, 2017. The show chronicles the weight loss ... television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted for ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation ... soon begin franchising throughout the U.S. starting this spring. Current Meditation focuses on ... of meditation mainstream. Current Meditation will be the first meditation concept in the ...
Breaking Medicine News(10 mins):